Login to Your Account


SAN FRANCISCO – In the wake of last year's hot IPO market, this year's climate is likely to be significantly cooler, giving way to between 25 and 30 U.S. biopharma IPOs, projected venture captialist Brent Ahrens and banker Jennifer Jarrett during a "crystal ball" panel at the CalBio 2015 conference.

Rather than seeking a new partner after a worldwide licensing deal with Roche AG quietly terminated last year, privately held Chiasma Inc. decided to take its new drug application (NDA)-ready oral octreotide to market in the U.S. on its own. And new and existing investors stepped up to help, to the tune of $70 million.

Cellectis SA, which last month disclosed plans to file for an IPO of American Depositary Shares (ADS) on the U.S. markets, dropped its paperwork, indicating it will seek to raise up to $115 million, including overallotments, and a listing on the Nasdaq Global Market under the ticker CLLS. The Paris-based company trades on the Alternext market of the Euronext Paris under the symbol ALCLS.

More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: